Investigation of the Cylex® ImmuKnow® Assay

Completed

• Conditions: Multiple Myeloma; Hodgkin's Disease; Myelodysplastic Syndromes; Leukemia; Chronic Lymphocytic Leukemia; Aplastic Anemia; Non-Hodgkin's Lymphoma; Myeloproliferative Disorders; Chronic Myelogenous Leukemia

• Registration Number: NCT00569842
• Lead Sponsor: Indiana University School of Medicine

Brief Summary

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Study First Submitted: 2007-12-05
• Study First Submitted QC: 2007-12-06
• Study First Posted: 2007-12-07
• Primary Completion: 2010-02
• Study Completion: 2012-12
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-10
• Last Update Posted: 2014-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

1. Acute leukemia
2. Non-Hodgkin's Lymphoma
3. Chronic lymphocytic leukemia
4. Hodgkin's disease
5. Multiple myeloma
6. Myelodysplastic Syndromes
7. Myeloproliferative Disorders
8. Aplastic Anemia
9. Chronic myelogenous leukemia

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Indiana Universtiy Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States